Antisense Technology

Antitumor Effect Exhibited by c-myc Antisense Phosphorothioate Oligodeoxynucleotides

Published in Gene Therapy Weekly, April 22nd, 1996

Antisense phosphorothioate oligodeoxynucleotides targeted to c-myc inhibit growth of human melanoma cells in vitro and in vivo.

Antisense oligodeoxynucleotides (ODNs) inhibit gene expression by forming RNA-DNA duplexes which prevent messenger RNA (mRNA) translation. Although commonly used to investigate the role of oncogenes in cancer development, and recently entered in clinical trials as therapeutic antineoplastic and anti-HIV agents, their use against solid tumors has only recently been explored.

Carlo Leonetti et al. evaluated the effects of antisense ODNs targeted to the c-myc oncogene on the proliferation of human melanoma cells...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1996-04-22)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry